Background. Early calcineurin inhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine practice, due to concerns about excess acute rejection. Therapeutic drug monitoring may be advantageous when the CNI or MMF is withdrawn. Methods. This prospective, randomized, concentration-controlled withdrawal study enrolled 177 stable renal transplant recipients on maintenance CNI-based immunosuppression, combined with steroids and MMF. After the feasibility phase of the study, patients were randomized to MMF-withdrawal (target area under the concentration-time curve-cyclosporine: 3250 ng·h/mL or tacrolimus: 120 ng·h/mL) or CNI-withdrawal (target area under the concentration-time curve-mycophenolic acid: 75 µg·h/mL). Results. The estimated glomerular filtration rate (modification of diet in renal disease) remained significantly better after CNI elimination (59.5±2.1 vs. 51.1±2.1 mL/min/1.73 m 2 ,
INTRODUCTION
Chronic allograft nephropathy (CAN), currently defined by interstitial fibrosis and tubular atrophy (IF/TA) 1 , is the most prevalent cause of late graft failure. IF/TA develops early after transplantation and is the consequence of the summated effects of tissue injury, dominated by acute rejection and calcineurin inhibitor (CNI)-related nephrotoxicity [2] [3] .
Progressive vasculopathy, including arteriolosclerosis, arteriolar hyalinosis, obliteration of peritubular capillaries and glomerular sclerosis become increasingly important over time [4] [5] .
Currently, early intervention strategies focus on developing immunosuppressive regimens, that allow CNI minimization and reduce CNI-associated toxicities, while maintaining low acute rejection rates [6] [7] . The results of these CNI minimization trials with interleukin-2-receptor blocker prophylaxis and mycophenolate mofetil (MMF), indicate that lower levels of CNI exposure are sufficient in de novo kidney transplant recipients. Minimization or, preferably, elimination of CNIs, appears to be a key decision to potentially modify long-term outcome [8] [9] . Early maintenance therapy with steroids and MMF, however, has not become routine practice, mainly due to concerns about acute rejection after CNI discontinuation 10 . Despite the documented salutary effects of MMF on acute rejection 11 , when used with CNIs and corticosteroids, several multicenter trials have underscored the increased risk of acute rejection episodes as the major limitation to complete CNI withdrawal 6, [12] [13] . It is important to note, however, that the risk of rejection in these studies was higher in patients with lower mycophenolic acid (MPA) exposure. The optimal range of MPA exposure in patients on reduced or no cyclosporine (CsA) was found to be higher than 30-60 µg·h/mL that is usually targeted in combination with CNIs 14 . Therapeutic drug monitoring may be advantageous when CNIs are withdrawn from a triple-drug regimen including MMF 13 . We hypothesized that adequate exposure before late withdrawal of either the CNI or MMF could significantly reduce the risk of acute rejection.
RESULTS

Study population
Of 177 patients entering the study, 158 patients were randomized to either CNI or MMF withdrawal between March 2003 and September 2007. Baseline characteristics were comparable with respect to demographic and transplant-related characteristics, such as donor age, histocompatibility, panel reactive antibodies, acute rejection history, time posttransplant, blood pressure (BP), lipid profile, renal function and proteinuria (Table 1) . (Table 2) .
Acute rejection
At 6 months, one patient in the MMF-withdrawal group (1.3%) and three in the CNIwithdrawal group (3.8%) experienced biopsy-proven acute rejection (BPAR, P=0.62) ( Table 3 ). The acute rejection episodes occurred after 161 (group B) and 75, 55 and 84 days (group C) after withdrawal, despite sufficient exposure of the CNI and MMF (see SDC, Table S2 , http://links.lww.com/TP/A647 4). None of the patients had an immunological risk profile predictive of acute rejection: none of them were highly immunized or had been treated for rejection before randomization. Only one patient had a high human leucocyte antigen mismatch (group B). One patient in group B (1.3%) and one in group C (1.3%) experienced BPAR late after withdrawal, after 991 and 369 days, respectively. In case of the late rejection in group B, there was suspicion of incompliance and the rejection in group C was most likely induced by underexposure to MPA (not documented) during a diarrhea episode due to cytomegalovirus (CMV) colitis. At 36 months, the incidence of BPAR was not significantly different between both groups (group B: 2.5% vs. group C: 5.1%; P=0.68; Table 3 ).
Chronic transplant dysfunction
During the study, 4 (5.1%) and 5 (6.3%) renal biopsies were performed because of chronic transplant dysfunction (CTD) in group B and C. Transplant glomerulopathy was diag- 
Patient and graft survival
The 3-year patient survival was 92.4% in the MMF-withdrawal group and 94.9% in the CNI-withdrawal group (P=0.75) ( Table 3 ). The 3-year graft survival censored for death was 98.7%, both in the MMF-withdrawal and CNI-withdrawal group (P=1.00). Causes of graft loss were CAN-IF/TA (group B) and chronic rejection (group C).
Treatment failure
Treatment failure defined by graft loss, patient death, acute rejection or change of immunosuppressive therapy was not different between the groups (Table 3 ). The main reason for reinstituting triple therapy was acute rejection in both regimens. Patients were switched to the other treatment arm because of adverse effects of the remaining drug: in case of the MMF-withdrawal group: CAN-IF/TA (1), gout (1), neuropathy (1), gingival overgrowth (1) and co-administration of verapamil (1); in case of the CNI-withdrawal group: diarrhea (2), recurrent infections (1), pancreatitis (1) and leucopenia, later definitely attributed to allopurinol (1).
Blood pressure and lipid profile
Systolic and diastolic BP decreased in both groups. At the end of the study, there were no significant differences in systolic and diastolic BP between the groups. There was a trend to use more antihypertensive drugs in the MMF-withdrawal group (Table 2) . Cholesterol and low density lipoprotein-cholesterol fell during the study, with no differences between the groups.
Adverse events
The defined MPA exposure was well tolerated; diarrhea occurred in only three patients in the CNI-withdrawal group (3.8%) ( Table 3 ). In retrospective, these patients already had diarrhea at inclusion, but had not mentioned this. Consequently, two of them were switched to dual therapy with steroids and a CNI. The other patient developed CMV-colitis and was switched to triple therapy because of acute rejection. Anemia (hemoglobin <7.0 mmol/L) was found more frequently in the CNI-withdrawal group (22.8% vs. 11.4%, P=0.06). One patient developed persistent leukocytopenia that resolved after cessation of allopurinol. There was no difference in the occurrence of single or recurrent infections, new onset diabetes mellitus or malignancies between the groups (Table 3) .
DISCUSSION
This study used therapeutic drug monitoring to adjust the dose of MMF or the CNI to the target levels in stable renal transplant patients before withdrawing one of the drugs from a triple-therapy regimen. Only 1 of 79 patients (1.3%) in the MMF-withdrawal group and 3 of 79 (3.8%) in the CNI-withdrawal group experienced acute rejection during the first 6 months after withdrawal. During the follow-up, patients were dosed based on infrequent AUC monitoring as it was a relatively low-risk population. Higher MPA exposure was well tolerated and late withdrawal of CNIs led to an immediate and significant improvement in renal function, remarkably also in patients with an eGFR less than 50 mL/min/1.73 m 2 (but still ≥30 mL/min/1.73 m 2 ). These findings are in line with previous studies regarding CNI withdrawal in patients with progressive deterioration of renal allograft function [16] [17] . The CONVERT trial showed that late CNI conversion to sirolimus resulted in better renal function, only for those with a baseline eGFR more than 40 mL/ min 18 . Our results extend these observations to maintenance therapy with MMF and patients with an eGFR more than or equal to 30 mL/min/1.73 m 2 .
The sustained increase in renal function directly after CNI withdrawal most likely resulted from reversal of renal vasoconstriction. CNIs cause acute reversible and chronic irreversible nephrotoxicity. Acute nephrotoxicity is induced by afferent arteriolar vasoconstriction, which is followed by a reduction in renal blood flow and GFR [19] [20] . Repeated daily episodes of renal vasoconstriction and ischemia might result in chronic structural changes of preglomerular vasculature, glomeruli and tubulointerstitium. Chronic CsA administration in a renal transplant rat model induced segmental sclerosis in glomeruli 21 . Additionally, CNIs induced upregulation of transforming growth factor-β, which may vary widely between individuals and on the renal molecular level [22] [23] [24] . Although CsA and tacrolimus are structurally different compounds, they have similar nephrotoxic potential at the clinical, histological and molecular level [24] [25] . The catalytic subunit of calcineurin consists of multiple isoforms and the α-isoform has a predominant role in kidney development 26 . Nephrotoxic changes associated with CNIs may be the result of chronic inhibition of α-activity in tubular epithelial cells. Mice lacking the α-isoform of calcineurin have impaired renal function and histological changes and matrix expansion with increased fibronectin and transforming growth factor-β comparable with CNIinduced nephrotoxicity in humans 27 . Despite dose adaptation, the actual CNI exposure remained higher than the predefined targets. This may also play a role in the observed renal function over time. This prospective controlled trial demonstrates that, in contrast with early withdrawal 6, 13, [28] [29] , late concentration-controlled CNI withdrawal was successful in more than 95% of patients, with a low risk of acute rejection. In the CAESAR study, CsA tapering between month 4 and 6, followed by withdrawal, resulted in 50% increase in acute rejection 6 .
Posthoc analysis, however, revealed that the risk of rejection was highest in patients with low MPA exposure, and that the optimal range of MPA exposure in patients on reduced or no CsA was close to 60 µg•h/mL 6 . This observation compares well with a study that evaluated acute rejection after withdrawal of CsA or MMF three months posttransplantation 30 . Low MPA exposure was shown to be an independent risk factor for acute rejection. In the Opticept trial, a maintenance regimen with concentration-controlled dosing of MMF combined with low dose CNI was not inferior with respect to the occurrence of acute rejection, indicating the utility of concentration-controlled exposure to MMF with CNI withdrawal 31 . It appears therefore critically important, that dosing and target concentrations of the remaining immunosuppressant are chosen such, that adequate overall immunosuppression is maintained during CNI minimization or withdrawal. Of note, none of the patients could have been predicted to have rejection based on their immunological risk profile. This underlines the importance of frequent examination of renal function during the first months after withdrawal. The 5-year follow-up study by Abramowicz reported that acute rejection also occurred long-term after CNI withdrawal 13 . During the follow-up of our study, only one patient in each group experienced a rejection episode, after the first year. One occurred as a consequence of CMV-colitis resulting in underexposure to MPA, the other one was related to incompliance with the prescribed CNI. This suggests that active AUC-monitoring prevented underexposure, and the occurrence of acute rejection at later time points. Physicians and patients should however be aware of the risk of underimmunosuppression in case of an intercurrent illness, especially with dual therapy. Despite the proof of principle, the current study has several limitations. This is a single-center study in a selected group of predominantly Caucasian kidney transplant recipients (78.5%) and consequently the results may not be directly extrapolated to other populations. Second, although the rejection rate in both withdrawal groups was low, the current study was not designed or powered to show a difference in this outcome. Outside the small feasibility phase, there was no control group continuing on triple immunosuppression. However, next to excellent prevention of acute rejection, it is also unlikely that graft function would have improved in a CNI-and MMF-based control group. Only 25% of patients in the MMF-withdrawal group continued with tacrolimus, whereas nowadays tacrolimus has become the most frequently prescribed CNI after renal transplantation. However, CsA and tacrolimus share similar nephrotoxic potential, and therefore our findings may be generalized to currently used regimens with tacrolimus and MMF. Finally, no protocol biopsies were obtained at the time of randomization or during follow-up to identify patients with subclinical rejection and/or CAN-IF/TA. According to the study protocol, a renal biopsy was performed when serum creatinine increased more than 15%. Because serum creatinine is a relatively insensitive marker, the rate of (subclinical) rejection or CAN-IF/TA may have been underestimated. In summary, late concentration-controlled CNI or MMF withdrawal can be safely implemented in the large majority of stable renal transplant recipients. To prevent insufficient immunosuppression, MMF and CNI doses can be adjusted based on exposure measurements. Maintaining low toxicity and adequate levels of the remaining immunosuppressant, CNI elimination may lead to improved graft and patient outcomes, especially in the increasingly prevalent proportions of recipients with extended criteria kidney transplants and gradual loss of renal function.
MATERIALS AND METHODS
Patients
Recipients of a first or second deceased or living donor kidney transplant, more than or equal to 6 months posttransplantation and on a CNI-based regimen (Cyclosporine, Novartis, Basel, Switzerland or Tacrolimus, FK506, Astellas Pharma, München, Germany), with corticosteroids and MMF (Cellcept, Hoffman-La Roche, Basel, Switzerland) were considered for enrollment. To be included, subjects must have had less than or equal to 2 rejection episodes after transplantation, no acute rejection during the 6 months before enrollment, and stable renal function with an MDRD clearance more than or equal to 30 mL/min/1.73 m 2 for at least 3 months. Exclusion criteria were chronic diarrhea or gastrointestinal disorders that interfere with the absorption of oral medication; active peptic ulcer disease; malignancy, except successfully treated nonmetastatic basal or squamous cell carcinoma of the skin; pregnancy or lactation; panel reactive antibodies more than 60% at the time of transplantation; current or historic treatment with unlicensed, investigational drugs or other prohibited medication; and (active) systemic infection (including CMV) requiring therapy at study entry.
Study design
Prospective, single-center, randomized open controlled study in stable kidney transplant recipients on a triple-drug regimen (Fig. 2) . The trial was performed in conformity with the Declaration of Helsinki, Good Clinical Practice guidelines. Informed consent was obtained from all patients. The study was approved by the Leiden University Medical Center ethics committee (ISRCTN81895822). The first (feasibility) phase randomized 58 patients (1:1:1) to MMF or CNI withdrawal or continuation of their current regimen (CsA-C 2 target 700 ng/mL). No acute rejection episodes occurred and the relatively high MMF doses were well tolerated after withdrawal. Encouraged by these results, in the second (extension) phase of the study another 119 patients were randomized (1:1) to the MMF-withdrawal or CNI-withdrawal group. All patients were stratified for the occurrence of previous acute rejection and prior cardiovascular events, defined as myocardial infarction or a percutaneous coronary intervention. At enrollment, systemic exposure (CNI and MPA) was assessed and patients were randomized using envelopes. The computer-generated randomization list and envelopes were provided by an independent trial pharmacist. Study visits were scheduled after 6 weeks and 3 monthly during the first year, and subsequently at 2 and 3 years. Follow-up of key parameters such as renal function, BP, serum lipids, hematologic parameters, malignancies, patient and graft survival were continued in each patient for 3 years to assess long-term outcome.
Treatment Plan
In eligible patients, systemic drug exposure (CsA or Tac, MPA) was measured by an AUC 0-12 before randomization to one of the study arms. We used a population-based two-compartmental pharmacokinetic model combined with Bayesian estimation and limited sampling as previously described [32] [33] . The limited sampling strategy for the CNIs included a trough level and additional levels 2 and 3 hours postdose. For MPA, blood samples were collected before and 1, 2 and 3 hours postdose. Systemic exposure was assessed at baseline, week 6 (2 weeks after withdrawal), month 6, year 1, year 2 and year 3. Doses were adjusted to reach the defined targets guided by an independent trial pharmacist. In case of unexpected large differences with previous results or, if required in relation to the patients clinical condition, more frequent assessments were initiated. Group A continued their current treatment regimen aiming at C 2 -levels of 700 ng/ mL (range: 600-800 ng/mL). In group B (MMF-withdrawal) CsA was dosed to reach the defined target AUC 0-12 of 3250 ng·h/mL (range: 3000-3500 ng·h/mL) and tacrolimus of 120 ng·h/mL (range: 100-140 ng·h/mL) before withdrawal. The targets and limited strategy have been described previously 25 . In group C (CNI-withdrawal) the MMF dose was adjusted to reach the defined MPA-AUC 0-12 target of 75 μg·h/mL (range: 60-90 μg·h/ mL) before withdrawal. The CNI or MMF dose was reduced 50% every two weeks and withdrawn after week 4. At the time of CNI withdrawal, the daily dose was temporarily increased to 20 mg/day for 1 week, followed by 15 mg/day the next week and than back to their maintenance dose. In stable renal transplant recipients on tacrolimus we maintained prednisolone at 5 mg/day, and 7.5 to 10 mg/day in all other patients.
Study end-points
Primary read-out was the change in creatinine clearance (eGFR estimated using the MDRD formula) after 3 years. Secondary endpoints included the number and severity of acute rejection episodes, CTD, graft loss, patient death, adverse events, BP and serum lipid profile. CTD was defined by the need to perform a renal biopsy in case of more than 15% deterioration of renal function. BP was measured in sitting position after 5 minutes rest using a digital BP monitor. Patients received concomitant medication according to defined standards for the treatment of hypertension (systolic BP<140 mm Hg and diastolic BP<90 mm Hg). Type, number and dosage of antihypertensive drug(s) were recorded during the study period. A target low density lipoprotein-cholesterol less than 2.6 mmol/L was defined for the whole study population. Any infection that required hospital admission was documented including site of infection and microorganism.
Statistical Methods and Power
The analyses were performed according to the intention-to-treat principle. A sample size of 63 evaluable patients per group was calculated to have 80% power to detect an increase of creatinine clearance of 10 mL/min, assuming a standard deviation of 20 mL/ min and α (2-z)=0.05. to analyze the longitudinal data of renal function in the withdrawal groups. Briefly, the model assumed that the MDRD clearance level at baseline of each patient might change after withdrawal and then follow a linear trend. The model had two parameters: the change of MDRD clearance after withdrawal with respect to baseline and the slope of the subsequent trend of the MDRD clearance. The parameters were assumed to be random and might differ between patients. The null hypotheses were tested that there were no differences in the two parameters between both groups. The analyses were performed using SPSS software (version 16.0). 
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